S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

NASDAQ:SPHS - Sophiris Bio Stock Price, Forecast & News

$0.72
-0.04 (-5.26 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$0.67
Now: $0.72
$0.76
50-Day Range
$0.53
MA: $0.71
$0.88
52-Week Range
$0.33
Now: $0.72
$1.20
Volume264,743 shs
Average Volume455,182 shs
Market Capitalization$24.82 million
P/E RatioN/A
Dividend YieldN/A
Beta2.38
Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SPHS
CUSIPN/A
Phone858-777-1760

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.06 per share

Profitability

Net Income$-6,780,000.00

Miscellaneous

Employees6
Market Cap$24.82 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive SPHS News and Ratings via Email

Sign-up to receive the latest news and ratings for SPHS and its competitors with MarketBeat's FREE daily newsletter.


Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions

What is Sophiris Bio's stock symbol?

Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."

How were Sophiris Bio's earnings last quarter?

Sophiris Bio Inc (NASDAQ:SPHS) announced its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.02. View Sophiris Bio's Earnings History.

When is Sophiris Bio's next earnings date?

Sophiris Bio is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Sophiris Bio.

What price target have analysts set for SPHS?

3 analysts have issued 12-month price targets for Sophiris Bio's stock. Their forecasts range from $2.80 to $6.00. On average, they anticipate Sophiris Bio's share price to reach $4.60 in the next year. This suggests a possible upside of 538.9% from the stock's current price. View Analyst Price Targets for Sophiris Bio.

What is the consensus analysts' recommendation for Sophiris Bio?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sophiris Bio.

Has Sophiris Bio been receiving favorable news coverage?

News coverage about SPHS stock has been trending very negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sophiris Bio earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Sophiris Bio.

Who are some of Sophiris Bio's key competitors?

What other stocks do shareholders of Sophiris Bio own?

Who are Sophiris Bio's key executives?

Sophiris Bio's management team includes the folowing people:
  • Dr. Lars G. Ekman M.D., Ph.D., Exec. Chairman (Age 69)
  • Mr. Randall E. Woods, CEO, Pres & Director (Age 67)
  • Mr. Peter T. Slover, Chief Financial Officer (Age 44)
  • Dr. Allison J. Hulme, COO, Head of R&D and Director (Age 56)
  • Dr. Samuel R. Denmeade, Chief Scientific Officer & Member of the Scientific Advisory Board

Who are Sophiris Bio's major shareholders?

Sophiris Bio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.66%) and Wedbush Securities Inc. (0.26%). View Institutional Ownership Trends for Sophiris Bio.

Which institutional investors are buying Sophiris Bio stock?

SPHS stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Sophiris Bio.

How do I buy shares of Sophiris Bio?

Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sophiris Bio's stock price today?

One share of SPHS stock can currently be purchased for approximately $0.72.

How big of a company is Sophiris Bio?

Sophiris Bio has a market capitalization of $24.82 million. The biopharmaceutical company earns $-6,780,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.View Additional Information About Sophiris Bio.

What is Sophiris Bio's official website?

The official website for Sophiris Bio is http://www.sophirisbio.com/.

How can I contact Sophiris Bio?

Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]


MarketBeat Community Rating for Sophiris Bio (NASDAQ SPHS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  292 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe SPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: Nikkei 225 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel